StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a hold rating to a buy rating in a research report released on Tuesday. Other equities research analysts have also issued reports about the stock. Evercore ISI decreased their target price on shares of Alnylam Pharmaceuticals from $252.00 to $210.00 in a research note […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-one brokerages that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month price target among […]
Oppenheimer downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from an outperform rating to a market perform rating in a report issued on Wednesday, Marketbeat Ratings reports. A number of other brokerages have also recently commented on ALNY. Royal Bank of Canada decreased their target price on shares of Alnylam Pharmaceuticals from $270.00 to […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price reduced by Citigroup from $266.00 to $233.00 in a research note released on Tuesday morning, MarketBeat.com reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on ALNY. Royal Bank of Canada restated an outperform […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price cut by Evercore ISI from $252.00 to $210.00 in a research note issued to investors on Tuesday morning, FlyOnTheWall reports. Other equities research analysts also recently issued research reports about the stock. Citigroup decreased their target price on shares of Alnylam Pharmaceuticals from $266.00 to […]